Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Oncotelic Therapeutics Inc (OTLC)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.0394 0.0000    0.00%
- Delayed Data. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.0360 - 0.0394
Oncotelic Therapeutics 0.0394 0.0000 0.00%

OTLC Recent Sentiments

 
This page contains information on users’ sentiments for the Oncotelic Therapeutics Inc stock, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
Feb 23, 2024 KEVIN SWENSON   0.0371 Mar 15, 2024 @ 0.0396 +6.74%
Jan 09, 2024 Giovanni Feltrin   0.0410 Feb 02, 2024 @ 0.0400 -2.44%
Dec 13, 2023 Giovanni Feltrin   0.0410 Jan 05, 2024 @ 0.0382 -6.83%
Aug 02, 2023 Giovanni Feltrin   0.0265 Nov 30, 2023 @ 0.0405 +52.83%
May 04, 2023 paola bastoni   0.0424 May 09, 2023 @ 0.0450 +6.13%
Jan 04, 2023 paola bastoni   0.0570 Jan 09, 2023 @ 0.0569 -0.18%
May 23, 2022 Don Jun   0.2270 May 30, 2022 @ 0.2325 +2.42%
May 04, 2022 Don Jun   0.2260 May 09, 2022 @ 0.2250 -0.44%
Feb 14, 2022 Miguel Angel Casla   0.1767 Feb 21, 2022 @ 0.2175 +23.09%
Nov 30, 2021 paola bastoni   0.1325 Dec 06, 2021 @ 0.1750 +32.08%
Nov 10, 2021 paola bastoni   0.1200 Nov 15, 2021 @ 0.1130 -5.83%
Oct 29, 2021 Massimo Agostinelli   0.1300 Nov 19, 2021 @ 0.1200 -7.69%
Aug 02, 2021 paola bastoni   0.1300 Aug 09, 2021 @ 0.1490 +14.62%
May 25, 2021 paola bastoni   0.3100 May 31, 2021 @ 0.2800 -9.68%
May 24, 2021 Giovanni Feltrin   0.2850 Jun 18, 2021 @ 0.2595 -8.95%
May 10, 2021 paola bastoni   0.3125 May 17, 2021 @ 0.3050 -2.40%
May 10, 2021 paola bastoni   0.3125 May 17, 2021 @ 0.3050 -2.40%
May 05, 2021 paola bastoni   0.2950 May 10, 2021 @ 0.2850 -3.39%
Apr 19, 2021 paola bastoni   0.2900 Apr 26, 2021 @ 0.3000 +3.45%
Apr 19, 2021 paola bastoni   0.2900 Apr 26, 2021 @ 0.3000 +3.45%
Apr 15, 2021 Giovanni Feltrin   0.3000 May 07, 2021 @ 0.2825 -5.83%
Apr 13, 2021 paola bastoni   0.2789 Apr 19, 2021 @ 0.2650 -4.98%
Apr 13, 2021 paola bastoni   0.2789 Apr 19, 2021 @ 0.2650 -4.98%
Apr 07, 2021 paola bastoni   0.2950 Apr 12, 2021 @ 0.2725 -7.63%
Mar 19, 2021 Giovanni Feltrin   0.2490 Apr 09, 2021 @ 0.2700 +8.43%
Mar 17, 2021 WHITE SHARK   0.2800 Apr 09, 2021 @ 0.2700 -3.57%
Mar 09, 2021 paola bastoni   0.2420 Apr 02, 2021 @ 0.2600 +7.44%
Feb 18, 2021 Giovanni Feltrin   0.3100 Mar 12, 2021 @ 0.2388 -22.97%
Jan 26, 2021 Ugo Fantozzi   0.3600 Feb 08, 2021 @ 0.2725 -24.31%
Jan 25, 2021 paola bastoni   0.3550 Feb 19, 2021 @ 0.2945 -17.04%
Jan 13, 2021 Giovanni Feltrin   0.2800 Feb 05, 2021 @ 0.2950 +5.36%
Dec 28, 2020 paola bastoni   0.2105 Jan 22, 2021 @ 0.3350 +59.14%
Dec 04, 2020 paola bastoni   0.1963 Dec 25, 2020 @ 0.2100 +6.98%
Nov 24, 2020 Анечка Тихомирова   0.1851 Dec 18, 2020 @ 0.2210 +19.39%
Nov 20, 2020 Giovanni Feltrin   0.1975 Dec 11, 2020 @ 0.2200 +11.39%
Sep 15, 2020 alan abbas   0.1797 Oct 09, 2020 @ 0.1860 +3.51%
Sep 01, 2020 Peter Meško   0.1801 Sep 25, 2020 @ 0.1800 -0.06%
Aug 19, 2020 Giovanni Feltrin   0.1850 Sep 11, 2020 @ 0.1775 -4.05%
Jul 22, 2020 Giovanni Feltrin   0.2150 Aug 04, 2020 @ 0.2600 +20.93%
Jul 13, 2020 paola bastoni   0.1950 Aug 07, 2020 @ 0.2200 +12.82%
Jul 03, 2020 alan abbas   0.1900 Jul 24, 2020 @ 0.2346 +23.47%
Jun 26, 2020 Giovanni Feltrin   0.1900 Jul 17, 2020 @ 0.1875 -1.32%
Apr 21, 2020 Giovanni Feltrin   0.1832 Apr 27, 2020 @ 0.1893 -3.33%
Apr 21, 2020 paola bastoni   0.2000 May 15, 2020 @ 0.1620 -19.00%
Apr 08, 2020 Yurii Ulytskyi   0.1950 Apr 13, 2020 @ 0.2080 +6.67%
Mar 18, 2020 Mario Alberti   0.1245 Apr 10, 2020 @ 0.1915 +53.82%
Mar 09, 2020 leonardo ceresa   0.1748 Apr 03, 2020 @ 0.1610 -7.89%
Mar 05, 2020 tatiana andena   0.1990 Mar 27, 2020 @ 0.1690 -15.08%
Mar 05, 2020 Andrea Di Cesare   0.1950 Mar 27, 2020 @ 0.1690 -13.33%
Mar 02, 2020 Riccardo Petruzzi   0.2200 Mar 27, 2020 @ 0.1690 -23.18%
More
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

OTLC Comments

Write your thoughts about Oncotelic Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
KEVIN SWENSON
KEVIN SWENSON Feb 23, 2024 1:46PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$Oncotelic Therapeutics Inc Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments $OTLC https://www.benzinga.com/partner/biotech/24/02/37210624/oncotelic-therapeutics-shares-groundbreaking-discovery-in-pediatric-brainstem-tumors-demonstratin
Reply
0 0
Report
Don Jun
Don Jun Apr 05, 2023 9:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Oncotelic Announces Release of Pet2DAO Tokens (PDAO): https://www.benzinga.com/pressreleases/23/04/g31629187/oncotelic-announces-release-of-pet2dao-tokens-pdao
Reply
0 0
Report
Don Jun
Don Jun Oct 17, 2022 6:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID: https://www.yahoo.com/now/oncotelic-awarded-barda-funding-development-110000810.html
Reply
0 0
Report
Don Jun
Don Jun Nov 16, 2021 9:30AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers: https://oncotelic.irpass.com/Oncotelic-Announces-Successful-Completion-of-the-Safety-Evaluation-of-a-TGF-946--Inhibitor--OT-101--and-IL-2--Aldesleukin--in-Phase-1-Combination-Trial-in-Solid-Tumor-Cancers-11-16-2021
Reply
0 0
Report
Don Jun
Don Jun Oct 05, 2021 6:36PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION:https://oncotelic.irpass.com/ONCOTELIC-ACQUIRES-FAST-TO-MARKET-LATE-STAGE-DRUG-CANDIDATE-FOR-PARKINSON-DISEASE--ERECTILE-DYSFUNCTION--AND-FEMALE-SEXUAL-DYSFUNCTION--10-4-2021
Reply
0 0
Report
Don Jun
Don Jun Sep 29, 2021 8:24PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
OT-101 – an antisense against TGF-β2 – for the treatment of solid tumors with focus on brain cancer in adult and DIPG in children. RPD for pediatric DIPG granted by US FDA. OT-101, also referred to Trabedersen, is a novel antisense oligodeoxynucleotide (ODN) developed by Oncotelic for the treatment of patients with pancreatic carcinoma, malignant melanoma, colorectal carcinoma, high-grade glioma (HGG), and other transforming growth factor beta 2 (TGF-β2) overexpressing malignancies (e.g., prostate carcinoma, renal cell carcinoma, etc.).
Reply
1 0
Report
Don Jun
Don Jun Sep 07, 2021 6:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION: https://oncotelic.irpass.com/ONCOTELIC-TO-ACQUIRE-LATE-STAGE-DRUG-CANDIDATE-FOR-PARKINSON-DISEASE--ERECTILE-DYSFUNCTION--AND-FEMALE-SEXUAL-DYSFUNCTION--9-1-2021
Reply
1 0
Report
Don Jun
Don Jun Aug 16, 2021 7:07PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ONCOTELIC AND GOLDEN MOUNTAIN PARTNERS FORMING A JOINT VENTURE FOR IPO:https://finance.yahoo.com/news/oncotelic-golden-mountain-partners-forming-110000184.html
Reply
1 0
Report
AP Cushman
AP Cushman Feb 26, 2021 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is at the level in which people that bought OCGN and BNGO got rich.
Reply
1 0
Report
Don Jun
Don Jun Feb 16, 2021 6:09PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™: https://finance.yahoo.com/news/mateon-partnered-chopra-foundation-artiveda-145200742.html
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email